Sage Therapeutics (NASDAQ: SAGE) today announced upcoming medical/scientific poster presentations at the American Epilepsy Society 69 th Annual Meeting, taking place from December 4-8, 2015 at the Pennsylvania Convention Center in Philadelphia, PA. The following is a schedule of SAGE's poster presentations: Date: Sunday, December 6, 2015 Presentation Time: 8:00 a.m. - 4:00 p.m. Location: Pennsylvania Convention Center, Exhibit Hall A, Level 200 Title: Anticonvulsant Efficacy of SAGE-217, a Second Generation Neuroactive Steroid, in a Mouse Model of Chronic Medial Temporal Lobe Epilepsy Date: Monday, December 7, 2015 Presentation Time: 8:00 a.m. - 2:00 p.m. Location: Pennsylvania Convention Center, Exhibit Hall A, Level 200 Title: Results of Phase I/II Trial of SAGE-547 for Super-Refractory Status Epilepticus (547-SSE-201) Response and Relationship to Underlying Patient Characteristics Date: Monday, December 7, 2015 Presentation Time: 8:00 a.m. - 2:00 p.m. Location: Pennsylvania Convention Center, Exhibit Hall A, Level 200 Title: Adaptation of a Pre-Clinical Biomarker for Allopregnanolone (SAGE-547) for Use in a Phase I/II Clinical Trial for Super-Refractory Status Epilepticus About Sage Therapeutics Sage Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.